Morgan Stanley
VIVO

Morgan Stanley’s Meridian Bioscience Inc VIVO Stock Holding History

Morgan Stanley’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-645,066
Closed -$21.4M – 7974
2022
Q4 		$21.4M Buy
645,066
+50,062
+8% +$1.61M ﹤0.01% 2269
2022
Q3 		$18.8M Buy
595,004
+194,099
+48% +$6.29M ﹤0.01% 2254
2022
Q2 		$12.2M Buy
400,905
+139,786
+54% +$3.78M ﹤0.01% 2858
2022
Q1 		$6.78M Sell
261,119
-54,164
-17% -$1.29M ﹤0.01% 3352
2021
Q4 		$6.43M Buy
315,283
+119,082
+61% +$2.28M ﹤0.01% 3455
2021
Q3 		$3.77M Buy
196,201
+18,351
+10% +$366K ﹤0.01% 4010
2021
Q2 		$3.94M Sell
177,850
-17,645
-9% -$374K ﹤0.01% 4030
2021
Q1 		$5.13M Sell
195,495
-19,905
-9% -$473K ﹤0.01% 3383
2020
Q4 		$4.03M Buy
215,400
+36,822
+21% +$688K ﹤0.01% 3492
2020
Q3 		$3.03M Sell
178,578
-8,327
-4% -$162K ﹤0.01% 3241
2020
Q2 		$4.35M Buy
186,905
+72,549
+63% +$1.05M ﹤0.01% 2819
2020
Q1 		$962K Sell
114,356
-103,076
-47% -$868K ﹤0.01% 3989
2019
Q4 		$2.12M Buy
217,432
+48,143
+28% +$452K ﹤0.01% 3988
2019
Q3 		$1.61M Sell
169,289
-32,001
-16% -$337K ﹤0.01% 3970
2019
Q2 		$2.39M Sell
201,290
-267,716
-57% -$3.23M ﹤0.01% 3643
2019
Q1 		$8.26M Sell
469,006
-155,809
-25% -$2.59M ﹤0.01% 2225
2018
Q4 		$10.8M Buy
624,815
+100,865
+19% +$1.72M ﹤0.01% 2041
2018
Q3 		$7.81M Buy
523,950
+191,623
+58% +$2.97M ﹤0.01% 2682
2018
Q2 		$5.28M Buy
332,327
+8,231
+3% +$123K ﹤0.01% 3078
2018
Q1 		$4.6M Sell
324,096
-93,750
-22% -$1.39M ﹤0.01% 3111
2017
Q4 		$5.85M Buy
417,846
+24,789
+6% +$363K ﹤0.01% 2937
2017
Q3 		$5.62M Buy
393,057
+288,307
+275% +$4.12M ﹤0.01% 2845
2017
Q2 		$1.65M Sell
104,750
-173,575
-62% -$2.5M ﹤0.01% 3962
2017
Q1 		$3.84M Sell
278,325
-131,187
-32% -$1.83M ﹤0.01% 3148
2016
Q4 		$7.25M Sell
409,512
-67,459
-14% -$1.19M ﹤0.01% 2600
2016
Q3 		$9.2M Sell
476,971
-16,510
-3% -$323K ﹤0.01% 2083
2016
Q2 		$9.62M Buy
493,481
+176,876
+56% +$3.47M ﹤0.01% 2013
2016
Q1 		$6.53M Sell
316,605
-85,663
-21% -$1.69M ﹤0.01% 2266
2015
Q4 		$8.26M Sell
402,268
-53,908
-12% -$1.03M ﹤0.01% 2167
2015
Q3 		$7.8M Sell
456,176
-49,330
-10% -$902K ﹤0.01% 2222
2015
Q2 		$9.42M Buy
505,506
+143,870
+40% +$2.67M ﹤0.01% 2174
2015
Q1 		$6.9M Buy
361,636
+90,740
+33% +$1.68M ﹤0.01% 2439
2014
Q4 		$4.46M Buy
270,896
+211,118
+353% +$3.62M ﹤0.01% 2836
2014
Q3 		$1.06M Buy
59,778
+17,444
+41% +$343K ﹤0.01% 3980
2014
Q2 		$875K Sell
42,334
-75,420
-64% -$1.55M ﹤0.01% 4165
2014
Q1 		$2.57M Sell
117,754
-70,998
-38% -$1.63M ﹤0.01% 3210
2013
Q4 		$5.01M Buy
188,752
+124,551
+194% +$3.06M ﹤0.01% 2563
2013
Q3 		$1.52M Buy
64,201
+38,483
+150% +$899K ﹤0.01% 3454
2013
Q2 		$554K Buy
+25,718
New +$555K ﹤0.01% 4188

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Morgan Stanley's VIVO Position: Q1 2023 in Review

Morgan Stanley sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 645,066 shares — an estimated $21.4M sold.

Morgan Stanley first reported a position in VIVO in Q2 2013 and held it in 39 quarters. The position peaked at $21.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Morgan Stanley reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Morgan Stanley sold 645,066 Meridian Bioscience Inc shares in Q1 2023, an estimated $21.4M.
  • Morgan Stanley first reported a position in Meridian Bioscience Inc in Q2 2013 and held it in 39 quarters.
  • Morgan Stanley's Meridian Bioscience Inc position peaked at $21.4M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.